KISS1 metastasis suppressor in tumor dormancy: a potential therapeutic target for metastatic cancers?
Harihar. Sitaram S; Welch. Danny R DR
Key Findings
- KISS1 acts as a metastasis suppressor by inducing dormancy in tumor cells at distant sites.
- Understanding the mechanisms of tumor dormancy is still limited, but KISS1 is a promising target for future therapies.
- Potential therapeutic strategies could involve either eliminating dormant cancer cells or maintaining them in a long‑term dormant state.
Practical Outcomes
- For the biohacker community, this review offers no immediate, actionable protocols or dosage guidance. It highlights a future research direction rather than a current tool for improving health or performance.
Summary
The paper reviews how the KISS1 gene can keep cancer cells in a dormant, non‑growing state and discusses the idea of using it as a new way to treat metastatic cancer. It does not provide any direct advice on how to use kisspeptin‑10 or related peptides for health, performance, or longevity.
Abstract
Present therapeutic approaches do not effectively target metastatic cancers, often limited by their inability to eliminate already-seeded non-proliferative, growth-arrested, or therapy-resistant tumor cells. Devising effective approaches targeting dormant tumor cells has been a focus of cancer clinicians for decades. However, progress has been limited due to limited understanding of the tumor dormancy process. Studies on tumor dormancy have picked up pace and have resulted in the identification of several regulators. This review focuses on KISS1, a metastasis suppressor gene that suppresses metastasis by keeping tumor cells in a state of dormancy at ectopic sites. The review explores mechanistic insights of KISS1 and discusses its potential application as a therapeutic against metastatic cancers by eliminating quiescent cells or inducing long-term dormancy in tumor cells.
Study Information
pubmed
2023
2023-01-31T00:00:00.000Z
10.1007/s10555-023-10090-6
11
168